Regulatory Requirements For Generic Drugs In India: Regulatory Framework, Approval Process, Challenges, And Future Perspectives

Abstract

Generic drugs play a vital role in improving access to affordable healthcare by providing therapeutically equivalent alternatives to innovator medicines at substantially lower costs. India is recognized as the "Pharmacy of the World" because of its extensive generic pharmaceutical manufacturing capacity and exports to more than 200 countries. Despite India's global leadership in generic medicine production, utilization of generic medicines within the country remains suboptimal due to limited public awareness, misconceptions regarding quality and efficacy, physician prescribing behavior, and inconsistent availability in certain regions. The regulatory framework governing generic drugs in India is primarily administered by the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. Over the past decade, several regulatory reforms have strengthened bioequivalence requirements, Good Manufacturing Practices (GMP), licensing procedures, and quality assurance mechanisms to improve public confidence in generic medicines. Government initiatives such as the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) have significantly enhanced the accessibility of affordable, quality-assured generic medicines across India. Nevertheless, several challenges remain, including inadequate awareness among healthcare professionals and patients, supply-chain limitations, regulatory disparities among states, and misconceptions regarding therapeutic equivalence. This review comprehensively discusses the regulatory framework for generic drugs in India, including approval procedures, CDSCO functions, bioequivalence requirements, GMP compliance, current regulatory reforms, comparative international standards, challenges, and future perspectives. Strengthening regulatory oversight, expanding public education, improving professional training, and ensuring continuous quality monitoring are essential for maximizing the benefits of generic medicines and achieving equitable healthcare delivery throughout India.